What Is Up For Biopharmaceutical Policy In 2024?

Attendees will gain an understanding of major policy changes and federal policy debates in 2024. The focus is anticipating the impact of these policy changes on product approval, launch and revenue expectations in the U.S. for in line and pipeline biopharmaceuticals.

Topics will include: Inflation Reduction Act Implementation, Anticipated Challenges in IP, Focus on M&A across the healthcare industry, and the overlay of drug pricing in all these debates.

Panel Discussion Moderated by John Stanford, Executive Director of Incubate, featuring:

Senator Richard Burr

Kirsten Axelsen, Senior Policy Advisor, DLA Piper

Gaurav Gupta, Managing Partner, J.P. Morgan Life Sciences Private Capital